Volume 2.03 | Jan 29

Immune Regulation News 2.03, January 29, 2010.
In this issue: Science News  |  Current Publications  |  Industry News  |  Policy News  |  Events Subscribe  |  Unsubscribe

TOP STORY

Study Reveals Unexpected Function for Seemingly Redundant Protein
Researchers have discovered the critical importance of TAB2, a protein previously believed to be a redundant "on switch" for certain immune-system responses. [North Carolina State University, Raleigh]

Request A Poster  
Isolate Untouched Cells for
Antigen Processing and Presentation
with EasySep®
 
 
REQUEST A POSTER STEMCELL Technologies Inc
 


SPECIAL FEATURE

Video – EasySep® – Powerful Immunomagnetic Isolation of Virtually Any Cell Type


SCIENCE NEWS

Biochemist Brian Baker Publishes Research on Protein Dynamics
A discovery at the University of Notre Dame reveals the importance of dynamic motion by proteins involved in the body’s immune response. [University of Notre Dame, Notre Dame]

New Therapeutic Approach Identified for Kidney Disease Associated With Lupus
Investigators have identified a new disease mechanism and therapeutic approach for a type of advanced kidney disease that is a common cause of complications in patients with lupus. [Hospital for Special Surgery, New York]

RoboSep_645x110_v01


CURRENT PUBLICATIONS

Temporal Changes in Dendritic Cell Subsets, Cross-Priming and Costimulation Via CD70 Control CD8+ T Cell Responses to Influenza
Researchers show here that influenza-specific CD8+ T cell priming was controlled by different dendritic cells at different times after infection. [Nat Immunol]

Natural Killer Cells Expressing Inhibitory Killer Cell Immunoglobulin-Like Receptors for Non-Self Ligands Remain Tolerant in HLA-Matched Sibling Stem Cell Transplantation
This study provides evidence against the emergence of alloreactive natural killer cells in HLA-identical allogeneic stem cell transplantation. [Blood]

Evidence for a Functional Role of IgE Anticitrullinated Protein Antibodies in Rheumatoid Arthritis
Exposure to citrullinated antigens leads to activation of basophils from anticitrullinated protein antibodies plus rheumatoid arthritis patients within 20 minutes. [PNAS]

Intracellular Major Histocompatibility Complex Class II Controls Regulatory Tolerance to Allogeneic Transplants
Results demonstrated the key role of major histocompatibility complex II in the induction of regulatory T cells. [J Immunol]

Absence of SHIP-1 Results in Constitutive Phosphorylation of Tank-Binding Kinase 1 and Enhanced Toll-Like Receptor-Dependent Interferon-Beta Production

Researchers have identified the inositol 5′ phosphatase SHIP-1 as a negative regulator of toll-like receptor 3-induced type I interferon production. [J Immunol]

Phospholipase C Gamma 2 Is Critical for Development of a Murine Model of Inflammatory Arthritis by Affecting Actin Dynamics in Dendritic Cells
This study demonstrates a critical role for phospholipase C gamma 2 in eliciting inflammatory responses by regulating actin dynamics in dendritic cells and positions the phospholipase C gamma 2 pathway as a common orchestrator of bone and immune cell functions during arthritis. [PLoS One]

Alpha-1,2-Mannosidase and Hence N-Glycosylation Are Required for Regulatory T Cell Migration and Allograft Tolerance in Mice
Researchers have identified that alpha-1,2-mannosidase expression increases in CD25+CD4+ regulatory T cells when they encounter alloantigen in vivo. [PLoS One]

Specific Gene Expression Signature Associated with Development of Autoimmune Type I Diabetes Using Whole-Blood Microarray Analysis
Results showed the presence of early functional modifications associated with type I diabetes, which could help to understand the disease and suggest possible avenues for therapeutic interventions. [Genes Immun]

NegSelRosetteSep_645x110_v01


INDUSTRY NEWS

Osiris Completes Enrollment in Stem Cell Trial for Type 1 Diabetes
Osiris Therapeutics, Inc. announced that it has achieved a $750,000 milestone payment from the Juvenile Diabetes Research Foundation for completing enrollment in a Phase II clinical trial evaluating Prochymal. [Osiris Therapeutics, Inc., Press Release]

Sanford Donates $50 Million for Biomedical Research
South Dakota banking mogul Denny Sanford has donated $50 million more to the Burnham Medical Research Institute in San Diego, California, which will be renamed the Sanford-Burnham Institute in honor of the gift. [Science]



POLICY NEWS

Advisory Committees; Tentative Schedule of Meetings for 2010 [Food and Drug Administration, United States]

Clarification of SF424 (R&R) Application Instructions for Resubmissions of Revision and Renewal Applications (NOT-OD-10-052) [National Institutes of Health, United States]

NINDS Ruth L. Kirschstein National Research Service Awards for Individual Predoctoral Fellows in MD-PhD programs (F31) (PAR-10-091) [National Institutes of Health, United States]

Notice of Availability of Administrative Supplements for Activities to Promote Research Collaborations for Projects Currently Funded by the NCI Division of Cancer Biology (NOT-CA-10-015) [National Cancer Institute, United States]

Participation of NCCAM on RFA-OD-10-009, Recovery Act Limited Competition: Methodology Development in Comparative Effectiveness Research (RC4) (NOT-AT-10-001) [National Center for Complementary and Alternative Medicine, United States]

EVENTS

9th International Conference on New Trends in Immunosuppression and Immunotherapy
February 4-6, 2010
Geneva, Switzerland

13th International Conference on Lymphocyte Activation and Immune Regulation: Inflammasome and Inflammation
February 5-7, 2010
Newport Beach, United States

Keystone Symposia: Tolerance and Autoimmunity
February 21-26, 2010
Taos, United States

World Immune Regulation Meeting – IV
March 29-April 1, 2010
Davos, Switzerland

American Association for Cancer Research (AACR) 101st Annual Meeting 2010
April 17-21, 2010
Washington, DC, United States

IMMUNOLOGY 2010
May 7-11, 2010
Baltimore, United States

14th International Congress of Immunology
August 22-27, 2010
Kobe, Japan

Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.


JOB OPPORTUNITIES

Business Development Europe – Cell Therapy Products (PALL Corporation)

Research & Development Scientist – Pancreatic Cell Biology (STEMCELL Technologies)

Research & Development Scientist – Endothelial Cell Biology (STEMCELL Technologies)

Research & Development Scientist – Epithelial Cell Biology (STEMCELL Technologies)

Recruit Top Talent

Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cell Therapy News.

Visit here to post your career opportunities.



Have we missed an important article or publication in Immune Regulation News? Click here to submit!

 

Learn more about Immune Regulation News: Archives  |  Events  |  Subscribe  |  Contact Us